{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:45:42Z","timestamp":1790520342210,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,5,5]],"date-time":"2012-05-05T00:00:00Z","timestamp":1336176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1136\/annrheumdis-2011-201282","type":"journal-article","created":{"date-parts":[[2012,7,8]],"date-time":"2012-07-08T01:01:25Z","timestamp":1341709285000},"page":"43-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":245,"title":["Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)"],"prefix":"10.1016","volume":"72","author":[{"given":"Maxime","family":"Dougados","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Kissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Sheeran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul P","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio Mart\u00edn","family":"Mola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Amital","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Navarro-Sarabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TWJ","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2011-201282_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ard.2009.123919","article-title":"Treating rheumatoid arthritis to target: recommendations of an international task force.","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201282_bib2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3899\/jrheum.090131","article-title":"Unmet needs in rheumatoid arthritis.","volume":"82","author":"Bykerk","year":"2009","journal-title":"J Rheumatol Suppl"},{"key":"10.1136\/annrheumdis-2011-201282_bib3","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/1529-0131(199809)41:9<1583::AID-ART8>3.0.CO;2-H","article-title":"Assessment of rheumatoid arthritis using a modified scoring method on digitized and original radiographs.","volume":"41","author":"Genant","year":"1998","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201282_bib4","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201282_bib5","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/ar1933","article-title":"Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low \u2013 results from RABBIT, the German biologics register.","volume":"8","author":"Listing","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2011-201282_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/ard.2010.139774","article-title":"Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.","volume":"70","author":"Soliman","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201282_bib7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/BOR.0b013e3283383f87","article-title":"Update on the use of conventional disease-modifying antirheumatic drugs in the management of rheumatoid arthritis.","volume":"22","author":"Feely","year":"2010","journal-title":"Curr Opin Rheumatol"},{"key":"10.1136\/annrheumdis-2011-201282_bib8","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2146\/ajhp070449","article-title":"Tocilizumab: the first interleukin-6-receptor inhibitor.","volume":"65","author":"Sebba","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1136\/annrheumdis-2011-201282_bib9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2011-201282_bib10","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/ibd.20949","article-title":"Magnifying colonoscopy used to predict disease relapse in patients with quiescent ulcerative colitis.","volume":"15","author":"Watanabe","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1136\/annrheumdis-2011-201282_bib11","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1136\/ard.2008.091454","article-title":"Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR\/ACR collaborative recommendations.","volume":"67","author":"Aletaha","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201282_bib12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study.","volume":"69","author":"Jones","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201282_bib13","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1002\/art.22033","article-title":"Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.","volume":"54","author":"Maini","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201282_bib14","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1136\/ard.2003.018457","article-title":"Deciding on progression of joint damage in paired films of individual patients: smallest detectable difference or change.","volume":"64","author":"Bruynesteyn","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201282_bib15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201282_bib16","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201282_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"Breedveld","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201282_bib18","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201282_bib19","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2011-201282_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-201282_bib21","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201282_bib22","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/ard.62.10.944","article-title":"Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study.","volume":"62","author":"Aletaha","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201282_bib23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10067-010-1500-9","article-title":"When should we use parenteral methotrexate?","volume":"29","author":"Mainman","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1136\/annrheumdis-2011-201282_bib24","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2008.094474","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-201282_bib25","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jbspin.2006.01.007","article-title":"Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion.","volume":"73","author":"Pavy","year":"2006","journal-title":"Joint Bone Spine"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724185615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724185615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2011-201282","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:42:24Z","timestamp":1739522544000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724185615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0003496724185615"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2011-201282","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2011-201282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}